Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Buspirone/carbidopa/levodopa - Nordic Life Science Pipeline

Next Previous
Search
Drug Profile

Buspirone/carbidopa/levodopa - Nordic Life Science Pipeline

Alternative Names: Buspirone/levodopa/carbidopa; Spinalon

Latest Information Update: 29 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Universite Laval
  • Developer National Institutes of Health (USA)
  • Class Antidepressants; Antiparkinsonians; Anxiolytics; Aromatic amino acids; Catecholamines; Hydrazines; Pyrimidines; Spiro compounds
  • Mechanism of Action 5-HT1A serotonin receptor agonists; Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Multiple sclerosis; Spinal cord injuries

Most Recent Events

  • 29 Aug 2023 No development reported - Phase-I/II for Spinal cord injuries in Canada (PO)
  • 28 Feb 2021 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (PO, Tablet)
  • 26 Feb 2019 Spinalon™ is still in phase I/II) trials for Spinal cord injuries and in preclinical trials for Multiple sclerosis in Canada (Nordic Life Science Pipeline, February 2019)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top